1. Home
  2. ETON vs HCAT Comparison

ETON vs HCAT Comparison

Compare ETON & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • HCAT
  • Stock Information
  • Founded
  • ETON 2017
  • HCAT 2008
  • Country
  • ETON United States
  • HCAT United States
  • Employees
  • ETON N/A
  • HCAT N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • HCAT Computer Software: Programming Data Processing
  • Sector
  • ETON Health Care
  • HCAT Technology
  • Exchange
  • ETON Nasdaq
  • HCAT Nasdaq
  • Market Cap
  • ETON 329.8M
  • HCAT 318.2M
  • IPO Year
  • ETON 2018
  • HCAT 2019
  • Fundamental
  • Price
  • ETON $14.22
  • HCAT $4.41
  • Analyst Decision
  • ETON Strong Buy
  • HCAT Buy
  • Analyst Count
  • ETON 3
  • HCAT 11
  • Target Price
  • ETON $27.67
  • HCAT $9.27
  • AVG Volume (30 Days)
  • ETON 248.9K
  • HCAT 963.8K
  • Earning Date
  • ETON 03-18-2025
  • HCAT 05-08-2025
  • Dividend Yield
  • ETON N/A
  • HCAT N/A
  • EPS Growth
  • ETON N/A
  • HCAT N/A
  • EPS
  • ETON N/A
  • HCAT N/A
  • Revenue
  • ETON $39,011,000.00
  • HCAT $306,584,000.00
  • Revenue This Year
  • ETON $107.69
  • HCAT $11.33
  • Revenue Next Year
  • ETON $65.50
  • HCAT $9.68
  • P/E Ratio
  • ETON N/A
  • HCAT N/A
  • Revenue Growth
  • ETON 23.29
  • HCAT 3.60
  • 52 Week Low
  • ETON $3.03
  • HCAT $3.76
  • 52 Week High
  • ETON $18.41
  • HCAT $9.24
  • Technical
  • Relative Strength Index (RSI)
  • ETON 43.84
  • HCAT 42.40
  • Support Level
  • ETON $12.73
  • HCAT $4.05
  • Resistance Level
  • ETON $15.73
  • HCAT $4.63
  • Average True Range (ATR)
  • ETON 0.93
  • HCAT 0.30
  • MACD
  • ETON -0.01
  • HCAT 0.07
  • Stochastic Oscillator
  • ETON 49.67
  • HCAT 64.57

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: